Literature DB >> 6236815

N-acetylglucosamine 6-sulfate residues in keratan sulfate and heparan sulfate are desulfated by the same enzyme.

J J Hopwood, H Elliott.   

Abstract

We have prepared a series of oligosaccharides to assess the substrate specificity of exo sulfatase activity in cultured human skin fibroblasts toward N-acetylglucosamine-6-sulfate residues present in keratan sulfate (KS) and heparan sulfate (HS). Non-reducing end alpha-GlcNAc-6-SO4 residues (derived from HS) were desulfated by a specific sulfatase that when deficient leads to the accumulation of HS and the expression of mucopolysaccharidosis type IIID (Sanfilippo D). Under the in vitro conditions studied there are two pathways for the degradation of oligosaccharides containing non-reducing end beta-GlcNAc-6-SO4 residues (derived from KS). In one pathway beta-N-acetylglucosaminidase produces GlcNAc-6-SO4 which is then desulfated. In the other pathway the beta-GlcNAc-6-SO4 residue is desulfated and then cleaved by the action of an beta-N-acetylglucosaminidase activity. There was no detectable beta-N-acetylglucosaminidase activity in fibroblasts from a Tay-Sachs patient to produce GlcNAc-6-SO4 from beta-GlcNAc-6-SO4 residues in KS of oligosaccharides. There was approximately 10% of this normal beta-N-acetylglucosaminidase activity in fibroblasts from a Sandhoff patient, suggesting the A and S forms may be involved in this reaction. Desulfation of GlcNAc-6-SO4 residues in KS, HS and the monosaccharide GlcNAc-6-SO4 was considerably reduced or not detected in fibroblasts from a Sanfilippo D patient. As KS was not detected in the urine of a Sanfilippo D patient we propose that KS degradation in these patients proceeds by the action of a beta-N-acetylglucosaminidase activity to produce GlcNAc-6-SO4 which is not further degraded.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6236815

Source DB:  PubMed          Journal:  Biochem Int        ISSN: 0158-5231


  9 in total

1.  Caprine mucopolysaccharidosis IIID: a preliminary trial of enzyme replacement therapy.

Authors:  E Downs-Kelly; M Z Jones; J Alroy; K T Cavanagh; B King; R E Lucas; J C Baker; S A Kraemer; J J Hopwood
Journal:  J Mol Neurosci       Date:  2000-12       Impact factor: 3.444

Review 2.  Glycan-based biomarkers for mucopolysaccharidoses.

Authors:  Roger Lawrence; Jillian R Brown; Fred Lorey; Patricia I Dickson; Brett E Crawford; Jeffrey D Esko
Journal:  Mol Genet Metab       Date:  2013-07-29       Impact factor: 4.797

3.  Purification of a 75 kDa protein from the organelle matrix of human neutrophils and identification as N-acetylglucosamine-6-sulphatase.

Authors:  Shengyuan Xu; Linshu Zhao; Anders Larsson; Emanuel Smeds; Marion Kusche-Gullberg; Per Venge
Journal:  Biochem J       Date:  2005-05-01       Impact factor: 3.857

4.  Human liver N-acetylglucosamine-6-sulphate sulphatase. Catalytic properties.

Authors:  C Freeman; J J Hopwood
Journal:  Biochem J       Date:  1987-09-01       Impact factor: 3.857

5.  Human liver N-acetylglucosamine-6-sulphate sulphatase. Purification and characterization.

Authors:  C Freeman; P R Clements; J J Hopwood
Journal:  Biochem J       Date:  1987-09-01       Impact factor: 3.857

6.  A cDNA clone for human glucosamine-6-sulphatase reveals differences between arylsulphatases and non-arylsulphatases.

Authors:  D A Robertson; C Freeman; C P Morris; J J Hopwood
Journal:  Biochem J       Date:  1992-12-01       Impact factor: 3.857

7.  Human liver glucuronate 2-sulphatase. Purification, characterization and catalytic properties.

Authors:  C Freeman; J J Hopwood
Journal:  Biochem J       Date:  1989-04-01       Impact factor: 3.857

8.  Urinary excretion of sulphated N-acetylhexosamines in patients with various mucopolysaccharidoses.

Authors:  J J Hopwood; H Elliott
Journal:  Biochem J       Date:  1985-08-01       Impact factor: 3.857

Review 9.  Pathogenic Roles of Heparan Sulfate and Its Use as a Biomarker in Mucopolysaccharidoses.

Authors:  Kohtaro Minami; Hideto Morimoto; Hiroki Morioka; Atsushi Imakiire; Masafumi Kinoshita; Ryuji Yamamoto; Tohru Hirato; Hiroyuki Sonoda
Journal:  Int J Mol Sci       Date:  2022-10-03       Impact factor: 6.208

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.